Scientific deep-dive
Five Hundred Calories at One Lunch
Researchers weighed what 114 people ate at a free-access lunch. Three weeks into tirzepatide they ate 524.6 fewer calories, without any increase in conscious dietary restraint.
Researchers sat 114 people down to a lunch they could eat as much of as they wanted, and weighed what they ate. Three weeks into tirzepatide, participants consumed 524.6 fewer calories at that meal than those on placebo.[1] The more interesting result is what the drug did not change: their conscious effort to restrict what they ate.
Why an ad libitum lunch
Most of what is known about how much people eat comes from food diaries, which are the weakest instrument in nutrition research. People under-report, forget, and record what they intended to eat. A laboratory meal with unlimited access, weighed before and after, removes all of that.
It buys objectivity at the cost of realism: one meal, in a laboratory, on a single day. What it measures it measures accurately.
| Measure | Result |
|---|---|
| Energy eaten at the lunch | −524.6 kcal (95% CI −648.1 to −401.0), P < 0.0001 |
| Overall appetite | Decreased |
| Food cravings | Decreased |
| Tendency to overeat | Decreased |
| Perceived hunger | Decreased |
| Reactivity to food in the environment | Decreased |
| Volitional restriction of dietary intake | Not changed |
The row at the bottom is the finding
People ate five hundred calories less without trying harder not to.
Volitional restriction measures deliberate effort, such as consciously holding back and choosing less. It did not move. Everything that did move sits upstream of effort: how hungry people felt, how much they craved, how strongly food in the environment pulled at them.
It also cuts against the framing that people on these drugs are taking a shortcut around discipline. On this evidence their discipline did not change; the thing it was being applied to got smaller.
The brain imaging, in the order it was found
A narrower finding did reach significance: activation to high-fat, high-sugar photographs specifically was reduced in four regions (the medial frontal and cingulate gyri, orbitofrontal cortex and hippocampus).
That is a sub-category within an imaging analysis, in named regions, after the aggregated outcome came back null. It is a reasonable finding to report and a poor one to lead with, and “brain scans show the drug reduces food reward” is how it will be summarized.
What limits it
- Phase 1, 114 people, six weeks, with the primary measurement at week three. This is a mechanism study, not an efficacy trial.
- One laboratory meal is not a day, a week, or a life. Whether a 500-calorie reduction at lunch persists across every meal is not what was measured.
- The design is asymmetric. Tirzepatide and placebo were blinded; the liraglutide arm was open-label. Participants who know what they are taking report subjective outcomes differently, so that arm cannot be read alongside the other two on appetite measures.
- Everyone was without diabetes, at a BMI between 27 and 50.
For why this effect fades over months, see why the appetite comes back; the proposed mechanism comes from work in mice.
Frequently Asked Questions
References
- 1.Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Nature Medicine. 2025. PMID: 40555748.
Compare the sellers
Related research
Taste Got Better, Not Worse
People on these drugs routinely say food tastes wrong. A trial measured taste objectively, biopsied participants' tongues and scanned their brains, and found taste recognition improved.
6 min read
How Zepbound Works: Tirzepatide's Two Receptors, Appetite and Fat Loss
Zepbound (tirzepatide) switches on the GIP and GLP-1 receptors. Its label says it lowers calorie intake through appetite, slows stomach emptying mostly after the first dose, and improves insulin response. In SURMOUNT-1 body scans, about three-quarters of the weight lost was fat.
8 min read
How Does Phentermine Work? Does It Burn Fat or Suppress Appetite?
Two FDA labels describe phentermine differently: one says it likely lowers appetite through catecholamine release in the hypothalamus, the other says appetite suppression is unproven as its main action. No human trial shows it burns fat, and tolerance sets in within weeks.
6 min read
Does Vaping or Nicotine Cause Weight Loss? What Smokers' Data Show
No study shows vaping causes weight loss. Nicotine modestly curbs appetite and raises calorie burn, but smokers who switched to e-cigarettes gained weight, and quitting adds about 4.7 kg in a year. What the evidence shows, and where GLP-1 drugs fit.
10 min read
Jardiance and Farxiga for Weight Loss: How Much, and Why It Stops
Jardiance and Farxiga cause about 2 kg of weight loss in type 2 diabetes and less without it, and neither is approved for weight. Why appetite cancels most of the sugar lost in urine, the side effects, and how they compare with Wegovy and Zepbound.
10 min read
The Thing That Makes Regain Inevitable
Metabolic adaptation is the leading explanation for why weight loss plateaus and returns. A study asked whether tirzepatide interrupts it. In mice it did; in people it did not.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →